Delivery Order FA486121D0004-FA486126F0084
Award Date 3/19/26
Potential Completion Date 9/15/26
Potential Value $42K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Nellis AFB, NV, Hoa Kỳ
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a delivery order awarded to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, for the provision of Oncotype cancer testing services to the Defense Health Agency (DHA). The contract has a ceiling value of $124,588.79 and a period of performance from March 16, 2025, to March 15, 2026, with the testing to be performed at Nellis Air Force Base in Nevada. The contract is a firm fixed-price type and does not have a set-aside designation. Genomic Health, Inc. is a for-profit...
- Genomic Health, Inc., a subsidiary of Exact Sciences Corp, has been awarded a $62,259.50 firm fixed price delivery order against an unspecified contract vehicle to provide oncotype dx cancer testing services for the United States Air Force Air Combat Command located at Nellis Air Force Base in Nevada. Oncotype dx cancer testing analyzes gene expression in breast and prostate cancers to determine a recurrence score that predicts the likelihood of cancer returning after initial treatment. The...
- The Defense Health Agency awarded Genomic Health, Inc. a $145,066.32 firm fixed-price BPA call for Oncotype IQ genomic testing services, with an ultimate completion date of September 7, 2026. Genomic Health, a subsidiary of Exact Sciences Corporation, specializes in advanced genetic testing services focused on oncology diagnostics, particularly the Oncotype DX portfolio of gene expression assays. These tests support cancer screening, treatment selection, and disease monitoring across breast,...
- The Department of the Air Force Air Combat Command awarded a $124,588.79 firm fixed price delivery order to Genomic Health, Inc. for Oncotype DX cancer testing services during the ordering period from March 2023 through March 2024. Genomic Health is a subsidiary of Exact Sciences Corporation which will perform the testing through its laboratory services division Exact Sciences Laboratories. The delivery order was awarded without a set-aside designation to support the Air Force's cancer screening...
- This is a firm fixed-price delivery order awarded by the Air Education and Training Command, a defense agency, to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation. The contract, valued at $3,453.96, is for the provision of Oncotype DX Pathology Tests, which are advanced genomic cancer diagnostic services. This order is placed under the Medical Laboratory Testing and Analysis Services contract vehicle, a General Services Administration (GSA) schedule. Genomic Health provides these...
- The Defense Health Agency awarded a $69.5K delivery order to Exact Sciences Corporation for Oncotype DX breast cancer genomic testing services, with performance at Eglin Air Force Base in Florida. This firm fixed-price contract, awarded September 26, 2025, represents a task order under the company's existing blanket purchase agreement with DHA for oncology testing services. Oncotype DX analyzes gene expression within breast cancer tumor tissue samples obtained from core biopsies or surgical...
- This federal contract award is for Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, to provide Oncotype DX cancer testing services to the U.S. Air Force's Air Combat Command. The delivery order is valued at $124,588.79 and has a period of performance from March 16, 2024 to March 15, 2025, with a total contract period extending to March 2025. Genomic Health has been awarded multiple prime federal contracts and task orders from agencies such as the Department of Veterans...
- This is a Definitive Contract awarded by the Defense Health Agency to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, for Oncotype DX cancer testing services. The $642,816.16 firm fixed-price contract covers the provision of these specialized genomic diagnostic services to various military and veterans' healthcare facilities, including Travis Air Force Base, from January 1, 2020 to March 31, 2025. Genomic Health, Inc. has significant federal Indefinite Delivery Vehicle (IDV)...
- The Defense Health Agency awarded a $145,066 firm fixed price blanket purchase agreement call contract to Genomic Health, Inc., a division of Exact Sciences Corporation, to deliver its Oncotype Portfolio of genomic tests for earlier cancer detection and cancer treatment. The testing portfolio aims to support the Defense Health Agency's efforts to advance cancer screening and personalized treatment selection. Performance will occur in Bethesda, Maryland over one year effective September 2023....
- The Defense Health Agency awarded a firm fixed price Blanket Purchase Agreement (BPA) call to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, for cancer testing services. The potential value of the contract is $124,081.53, with a completion date of September 30, 2019. Genomic Health has provided cancer testing services, including its Oncotype DX portfolio of assays, to the Department of Defense and Department of Veterans Affairs under past federal contracts. This award is...